iBio, Inc. has entered into the initial Statement of Work (SOW1) under its Memorandum of Understanding (MOU) with AzarGen Biotechnologies. Following the successful use of iBio’s technologies and manufacturing capabilities to advance the development of AzarGen’s surfactant protein therapeutic through an initial assessment of production feasibility, in May 2017, the two companies expanded their collaboration by initiating the development of a plant-made rituximab for the South African market un...